The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) to permit the emergency use of BNT162b2 (SARS-CoV-2-mRNA Vaccine), which is not an FDA-approved vaccine, for active immunization against COVID-19

Medical Information
United States

In order to provide you with relevant and meaningful content we need to know more about you.

Please choose the category that best describes you.

This content is intended for U.S. Healthcare Professionals. Would you like to proceed?

May 15, 2020

The U.S. Food and Drug Administration (FDA) has authorized the emergency use of the investigational product Pfizer-BioNTech COVID-19 Vaccine for active immunization to prevent coronavirus disease 2019 (COVID-19) in individuals 12 years of age and older. The vaccine has not been approved, but is authorized under an Emergency Use Authorization only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of the vaccine under section 564(b)(1) of the Act, 21 U.S.C. ยง 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.